Orbimed closes $500m venture fund
The New York-based firm says investors flocked to its third fund to focus on late-stage life science companies.
The New York-based firm says investors flocked to its third fund to focus on late-stage life science companies.
Copyright PEI Media
Not for publication, email or dissemination